U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Lung Non-Small Cell Carcinoma

MedGen UID:
1651777
•Concept ID:
C4744438
•
Neoplastic Process
Synonym: Unresectable Non-Small Cell Lung Carcinoma

Definition

Lung non-small cell carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Lung Non-Small Cell Carcinoma

Professional guidelines

PubMed

Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
Yılmaz U, Yasar Z, Korkmaz E, Yalcın B, Koparal H, Ozbilek E
Med Glas (Zenica) 2017 Aug 1;14(2):204-210. doi: 10.17392/898-17. PMID: 28698535

Recent clinical studies

Etiology

Current and Future Treatment Options in the Management of Stage III NSCLC.
Li Y, Juergens RA, Finley C, Swaminath A
J Thorac Oncol 2023 Nov;18(11):1478-1491. Epub 2023 Aug 11 doi: 10.1016/j.jtho.2023.08.011. PMID: 37574133
Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.
Verfaillie S, Lambrecht M, Berkovic P, Dooms C, Nackaerts K, Van de Velde AS, Vansteenkiste J, Wauters E
Cancer Treat Res Commun 2023;36:100727. Epub 2023 Jun 7 doi: 10.1016/j.ctarc.2023.100727. PMID: 37307680
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A
J Clin Oncol 2022 Oct 10;40(29):3383-3393. Epub 2022 Apr 22 doi: 10.1200/JCO.22.00227. PMID: 35452273
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL
Lancet Oncol 2022 Feb;23(2):209-219. Epub 2022 Jan 14 doi: 10.1016/S1470-2045(21)00630-6. PMID: 35038429
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Diagnosis

Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y
Cancer Commun (Lond) 2024 Jan;44(1):23-46. Epub 2023 Nov 20 doi: 10.1002/cac2.12505. PMID: 37985191Free PMC Article
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K
JAMA Netw Open 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. PMID: 38100106Free PMC Article
Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.
Verfaillie S, Lambrecht M, Berkovic P, Dooms C, Nackaerts K, Van de Velde AS, Vansteenkiste J, Wauters E
Cancer Treat Res Commun 2023;36:100727. Epub 2023 Jun 7 doi: 10.1016/j.ctarc.2023.100727. PMID: 37307680
Advances in systemic therapy for non-small cell lung cancer.
Miller M, Hanna N
BMJ 2021 Nov 9;375:n2363. doi: 10.1136/bmj.n2363. PMID: 34753715
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Therapy

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J, Antonia S, Wu YL, Cho BC, Thiyagarajah P, Mann H, Newton M, Faivre-Finn C
J Thorac Oncol 2023 May;18(5):657-663. Epub 2023 Feb 24 doi: 10.1016/j.jtho.2023.02.009. PMID: 36841540
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL
Lancet Oncol 2022 Feb;23(2):209-219. Epub 2022 Jan 14 doi: 10.1016/S1470-2045(21)00630-6. PMID: 35038429
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
Lu S, Casarini I, Kato T, Cobo M, Özgüroğlu M, Hodge R, van der Gronde T, Saggese M, Ramalingam SS
Clin Lung Cancer 2021 Jul;22(4):371-375. Epub 2021 Jan 6 doi: 10.1016/j.cllc.2020.11.004. PMID: 33558193
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators
N Engl J Med 2018 Dec 13;379(24):2342-2350. Epub 2018 Sep 25 doi: 10.1056/NEJMoa1809697. PMID: 30280658
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators
N Engl J Med 2017 Nov 16;377(20):1919-1929. Epub 2017 Sep 8 doi: 10.1056/NEJMoa1709937. PMID: 28885881

Prognosis

Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y
Cancer Commun (Lond) 2024 Jan;44(1):23-46. Epub 2023 Nov 20 doi: 10.1002/cac2.12505. PMID: 37985191Free PMC Article
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
Lu S, Casarini I, Kato T, Cobo M, Özgüroğlu M, Hodge R, van der Gronde T, Saggese M, Ramalingam SS
Clin Lung Cancer 2021 Jul;22(4):371-375. Epub 2021 Jan 6 doi: 10.1016/j.cllc.2020.11.004. PMID: 33558193
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H
J Clin Oncol 2020 Mar 1;38(7):706-714. Epub 2019 Dec 16 doi: 10.1200/JCO.19.01162. PMID: 31841363Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Clinical prediction guides

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B
J Thorac Oncol 2023 Feb;18(2):181-193. Epub 2022 Oct 25 doi: 10.1016/j.jtho.2022.10.003. PMID: 36307040
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI
Front Immunol 2022;13:823618. Epub 2022 Feb 9 doi: 10.3389/fimmu.2022.823618. PMID: 35222404Free PMC Article
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H
J Clin Oncol 2020 Mar 1;38(7):706-714. Epub 2019 Dec 16 doi: 10.1200/JCO.19.01162. PMID: 31841363Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Recent systematic reviews

Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review.
Allignet B, De Ruysscher D, Martel-Lafay I, Waissi W
Cancer Treat Rev 2023 Jul;118:102573. Epub 2023 May 19 doi: 10.1016/j.ctrv.2023.102573. PMID: 37210766
Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Li X, Wang F, Jia H, Lian Z, Ren K, Yuan Z, Wang P, Zhao L
Future Oncol 2022 Sep;18(27):3055-3065. Epub 2022 Aug 10 doi: 10.2217/fon-2022-0491. PMID: 35947522
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D
J Clin Oncol 2022 Feb 10;40(5):492-516. Epub 2021 Dec 21 doi: 10.1200/JCO.21.02314. PMID: 34932393
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA
J Thorac Oncol 2020 Aug;15(8):1281-1297. Epub 2020 Jun 6 doi: 10.1016/j.jtho.2020.05.020. PMID: 32522713
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS
JAMA Oncol 2017 Aug 1;3(8):1120-1129. doi: 10.1001/jamaoncol.2016.4280. PMID: 27978552

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...